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Summary 
Previous attempts at identifying the constitutive source(s) of granulocyte colony-stimulating factor 
(G-CSF) in human bone marrow have been unsuccessful despite the fact that normal bone marrow 
supports abundant myelopoiesis in vivo. We hypothesized that the intimate physical association 
between bone and hematopoietic cells facilitates interactions between osteoblasts and hematopoietic 
stem  cells.  Here  we  provide  the  first  direct  evidence  that  human  osteoblasts  participate  in 
hematopoiesis by constitutively producing G-CSF and present the protein in a membrane-associated 
fashion to human hematopoietic progenitors.  These results suggest a direct and central role for 
osteoblasts in normal  myelopoiesis. 
H 
ematopoietic stem cell differentiation  after birth is largely 
restricted to the bone marrow cavity. Whether osteo- 
blasts and bone matrix provide essential adhesive,  stimula- 
tory, or regulatory signals to stem cells is not known. Overall, 
the unique physiological conditions that bone tissue provides 
for hematopoietic cells is essentially a mystery. Mesenchymal 
cells of fibroblast origin,  dispersed throughout  the marrow 
cavity, secrete cytokines such as GM-CSF, IL-6, and c-kit ligand 
to support basal hematopoiesis,  and respond to inflamma- 
tory monokines by secreting large quantities of GM-CSF and 
G-CSF  (1-7).  This cytokine secretion profile is not,  how- 
ever, specific to bone marrow and is shared by fibroblasts from 
many tissues.  In addition,  in the absence of inflammation 
human fibroblasts do not produce G-CSF, and the source of 
basal G-CSF production  that  supports normal  granulopoi- 
esis is unknown  (6,  7). 
The development of the bone marrow cavity is a coordi- 
nated process in which blood precursors migrate and colo- 
nize spaces carved out of embryonic bone and cartilage (8). 
Thus, an intimate physical association between bone cells and 
blood cells  is established early in life.  Since (a) osteoblasts 
are found on endosteal marrow surfaces;  (b) primitive hema- 
topoietic stem cells  are closely approximated  with the en- 
dosteal surfaces rather than randomly distributed throughout 
the marrow cavity; and (c) many stromal cell lines share sev- 
eral  phenotypic characteristics  with  osteoblasts (9-14),  we 
hypothesized that  osteoblasts might  directly support  stem 
cell survival and/or  differentiation.  In particular  we asked 
whether osteoblasts might be a heretofore undetermined source 
of constitutively  produced  G-CSF  in  the  bone  marrow 
microenvironment. 
Materials  and Methods 
Human Osteoblasts.  "Human  osteoblasts were obtained using a 
modification  of methods  described by Robey and Termine (15). 
Normal human trabecular bone was obtained from patients under- 
going orthopedic  surgery in accordance with the University  of 
Michigan's Policies for Human Subjects. Bone cleaned of loosely 
adherent tissue was ground to produce a uniform particle size (size 
~<1 mm 2) (BioComp MinimiU; W. Lorenz, Jacksonville, FL) and 
incubated in  1 mg/ml bacterial coUagenase (Type P; Boehringer 
Mannheim Biologicals, Indianapolis, IN). The explants were placed 
into  culture  until confluent  monolayers were produced  in a 1:1 
(vol/vol) mixture of F12/DMEM medium (Biofluids Inc., Rock- 
ville, MD) with low Ca +2 and  10%  FCS. Thereafter,  cultures 
were  maintained  in  calcium-replete  DMEM/F12  (1:1 vol/vol) 
medium containing 10% heat inactivated FCS, antibiotics, 10 mM 
B-glycerophosphate, and 10 mg/ml t-ascorbate. To verify that the 
cells were osteoblasts, several histochemical assays were performed 
including in vitro mineralization,  and expression of high levels of 
alkaline phosphatase (16). 
RNA Preparation.  Total cellular KNA was recovered from os- 
teoblasts as reported  in (7).  RNA quantity and integrity were 
checked by gel electrophoresis with ethidium bromide and absor- 
bance at A~/A2s0. 
Oligonucleotide Primers.  Sense  and antisense primers were pre- 
pared by the oligonucleotide  synthesis core at the University  of 
Michigan. The primers used in these investigations were reported 
previously (7) with the exceptions of those for osteocalcin (nu- 
cleotides  1046-1066 sense) GGCAGCGAGGTAGTGAAGAG 
and  (nucleotides  1364-1384,  antisense) GATGTGGTCAGCCA- 
ACTCGT. 
Reverse Transc@tase Polymerase Chain Reaction (RT-PCR).  RT- 
PCtL was performed for 35 cycles as previously reported (7). PCR 
products were electrophoresed in 3% agarose and visualized with 
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lated from either peripheral blood lymphocytes stimulated with 
PHA (3.0 #g/ml) and PMA (3 ng/ml) or IL-lc~  (25 U/m1) stimu- 
lated human bone marrow stromal cells. To control for DNA con- 
tamination, reverse transcriptase  was omitted from the reverse tran- 
scriptase reaction. 
ELISAs.  G-CSF  ELISAs were performed using the double- 
antibody sandwich  method (R&D Systems  Inc., Minneapolis,  MN). 
Based upon parallel assays of known diluted standards, the sensi- 
tivities of the assays for  G-CSF in  unconcentrated  medium is 
25-2,000 pg/ml. Aliquots of conditioned medium were concen- 
trated 4-10-fold by centrifugation at 1,000 g in a 25~  fixed angle 
JA-17 rotor (Beckman Instruments  Inc., Fullerton, CA) in Cen- 
tricon-10 concentrators (Amicon Division ofW. R. Grace and Co., 
Beverly, MA) until the desired volume was reached. Used in con- 
junction with concentrated medium, the G-CSF ELISA was able 
to detect concentrations as low as 4 pg/ml. 
Immunohistochemistry.  Indirect immunohistochemistry phase- 
contrast microscopy  was performed  for G-CSF on 2% paraformalde- 
hyde-fixed  primary human osteoblasts grown in 96-well tissue cul- 
ture plates. Paraformaldehyde-fixed  primary human osteoblasts  were 
incubated with 10/~g/ml of a murine monoclonal anti-human 
G-CSF in PBS (M7; kind gift of Dr. Michael Widmer, Immunex 
Corporation, Seattle, WA) or an isotype control (FOPC-21, Sigma 
Chemical Co., St. Louis, MO) at 4~  for two hours followed by 
a rabbit antimurine  FITC-conjugated serum at a 1/64  dilution 
(Sigma Chemical Co.). Nonspecific  binding was blocked with 10% 
normal rabbit serum. 
Isolation  of CD34 + Cells.  Bone marrow cells obtained from 
healthy adult volunteers were diluted 1:4 (vol/vol) in IMDM and 
separated by density separation on Ficoll-Hypaque (specific  gravity 
1.077) to recover mononuclear cells. After two rounds of plastic 
adherence at 370C for 1 h each in IMDM medium with 20% FCS 
(to remove monocytes, platelets, and megakaryocytes),  the nonad- 
herent  cells were recovered. CD34 §  hematopoietic progenitor 
populations were isolated using an avidin-biotin immunoaffinity 
process (CellPro Inc., Bothell, WA). 
Coculture of NFS-60,  CD34 +, and Osteoblasts.  CD34  + or NFS- 
60  cells were  seeded directly onto  osteocalcin  +,  c-kit  ligand- 
confluent osteoblast monolayers  in 96-well tissue culture plates at 
a final density of 104 cells/well and incubated for 3-14 d. Either 
vehicle, 10 #g/weU of  an a~nity purified  IgG fraction  of  neutralizing 
goat anti-human G-CSF serum (R&D Systems), or 10/~g/well 
of normal goat IgG serum were added to cultures daily. Absolute 
cell numbers were determined by manual hemocytometer counting 
in PBS containing 0.4%  trypan blue (Sigma Chemical Co.). 
Figure 1.  RT-PCR  detection  ofcytokine  mRNA  by (A) primary  human 
osteoblasts and (B) stromal  cells. RT-PCR was performed  using primers 
for IL-Ic~,  TNF, lymphotoxin  (LT), IL-6, G-CSF, GM-CSF,  IL-3,  c-kit ligand, 
and osteocalcin. Negative  controls omitted  reverse transcriptase  from the 
reverse transcription reaction. RNA from IL-13 and TNF-c~ stimulated 
stromal cells served as positive controls for G-CSF and c-kit ligand. 
Results and Discussion 
We first determined whether unstimulated primary human 
osteoblasts are a normal source of G-CSF. Primary osteoblasts 
were obtained using the methods of Robey and Termine (15), 
where osteoblasts emerge from collagenase-digested human 
bone during the second to third week of culture. We found 
that these cells express several functional characteristics of os- 
teoblasts including the expression of mRNA for matrix Gla 
protein (not shown) and the osteoblast-specific  protein, os- 
teocalcin (bone Gla protein) (16-18)  (Fig.  1), mineralization 
of their extracellular matrix, and the expression of alkaline 
phosphatase examined by histochemical methods (data not 
shown) (16). 
Primary human osteoblast cultures were examined for their 
expression  of mRNA for several cytokines using RT-PCR. 
As shown in Fig. 1, osteoblasts constitutively express mRNA 
for several cytokines including TNF-a, IL-6, GM-CSF, and 
G-CSF,  but failed to express mRNA for IL-loe, IL-3, and 
c-kit  ligand.  As c-kit  ligand is constitutively produced by 
stromal fibroblasts,  the absence of detectable mRNA for this 
hematopoietic growth factor suggests minimal fibroblast con- 
tamination in the primary cultures (Fig.  1 and 4,  6, 7). To 
further assure that these results are representative  of normal 
osteoblast physiology, we induced the differentiation of os- 
teoblasts from nonadherent low density bone marrow os- 
teoprogenitors using a serum deprivation method (19). A 
similar cytokine profile was observed for these osteocalcin +, 
c-kit ligand- cells. In addition, we noted a comparable pat- 
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cubated with (C) 10/~g/ml of routine monoclonal  anti-human G-CSF in PBS or (B) an isotype  control at 4~  for 2 h followed  by a rabbit antimurine 
FITC-conjugated serum at a 1:64 dilution (Sigma Chemical Co.). Nonspecific  binding was blocked  with 10% normal rabbit serum. 
tern of cytokine mRNAs expressed by the human osteosar- 
coma cell lines, MG-63  and SaOSo2  (data not  shown). 
The ILT-PCR results suggest that osteoblasts  constitutively 
express G-CSF mRNA. We next asked whether the G-CSF 
message is translated and how the protein is presented to heo 
matopoietic progenitors. To determine whether the G-CSF 
message is translated, we performed immunohistochemical 
staining for G-CSF on paraformaldehyde-fixed  primary human 
osteoblasts using a monoclonal anti-human G-CSF antibody. 
As shown in Fig. 2, G-CSF is localized on the cell membrane 
of the osteoblasts and not in the interstitial extracellular ma- 
trix. To quantify G-CSF production from unstimulated os- 
teoblasts expressing G-CSF mRNA, salt extracts of extracel- 
lular matrix (20, 21) and concentrated, conditioned medium 
were analyzed for G-CSF by ELISA (7). As positive controls 
for G-CSF production, osteoblasts or stromal cells were ex- 
posed to lipopolysaccharide or IL-lc~, respectively (22-24). 
LPS stimulation of osteoblasts resulted in the production of 
21 pg/ml/24 h/104 cells of soluble G-CSF. No G-CSF could 
be detected in the medium or extracellular matrix of unstimu- 
lated osteoblasts, suggesting that under basal conditions G- 
CSF may not be released as a soluble protein. 
To determine whether the G-CSF detected by immuno- 
histochemical methods has functional activity, we evaluated 
the proliferation of the G-CSF-dependent cell line NFS-60 
in coculture with osteocalcin  +, c-kit ligand-  human explant 
osteoblasts (25). A neutralizing antibody to human G-CSF 
was used to directly test whether osteoblast-derived G-CSF 
has biological activity.  As  shown in  Fig.  3,  NFS-60 cells 
proliferate in the presence of osteoblast monolayers but not 
in medium alone. Inclusion of a neutralizing anti-G-CSF an- 
tibody in the cultures caused a 41% reduction in the prolifer- 
ation of the NFS-60 cells. The proliferation of NFS-60 cells 
was not affected by a control antiserum nor were significant 
differences in proliferation of the NFS-60 cells observed when 
the cells were grown in osteoblast-conditioned medium (50% 
vol/vol) alone, with or without the neutralizing anti-human 
G-CSF  antibody. 
These results obtained with the NFS-60 cell line suggest 
that osteoblasts might stimulate the proliferation of human 
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Figure  3.  NFS-60  cell  proliferation  on osteoblast monolayers.  NFS-60 
cells were seeded onto confluent  human osteoblasts at a final density of 
104 cells/well  in 96-well  tissue culture  plates for 3 d. Where indicated ve- 
hicle (no AB), 10/zg/well  of  an affinity  purified  IgG fraction  of  neutralizing 
goat anti-human G-CSF serum (Anti-G-CSF) or 10/~g/we11 of normal 
goat IgG serum (control AB) were added daily. Absolute NFS-60 cell 
numbers were  determined  by manual  hemocytometer  counting  and reported 
as mean _+ SD (n  =  4). (Asterisk) Significant  difference  from antibody 
or vehicle control, p <0.01. 
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Figure  4.  Human  CD34  § cells obtained by affinity  purification of 
nonadherent low density  mononuclear  bone marrow cells (CellPro Inc.) 
were seeded directly  into 96-well tissue culture plates or onto confluent 
osteocalcin  + c-kit ligand- human osteoblast monolayers  at a final den- 
sity of 104 cells/well  and incubated  for 14 d. The Results of one of two 
experiments are presented. Where  indicated  vehicle (no AB), 10/Lg/well 
of either neutralizing  goat anti-human G-CSF serum or goat IgG serum 
(control AB) were added daily  (R&D Systems). Cell counts  were deter- 
mined  by manual  hemocytometer  counting  and are reported  as mean -+ SD 
(n = 3). The hematopoietic  cells recovered after  2 wk of coculture  main- 
tained an immature  (23 _+ 6% myeloblasts/promyelocytes;  51.7 + 5.5% 
myelocytes/metamyelocytes;  21 + 5% bands/polymorphonudear  neutro- 
phils; and 4.3 _+ 0.6% monocytes,  treatment  with anti-G-CSF  reduced 
the recovery of band/polymorphonuclear  neutrophils to 8.7  _+  10%). 
(Asterisk) Significant  difference  from  antibody  or vehicle  control,  p <0.01. 
hematopoietic progenitors by producing G-CSF. To examine 
this possibility, CD34 + hematopoietic progenitor cells were 
isolated and seeded into confluent osteocalcin +, c-kit ligand- 
osteoblast monolayers. At 14 d the hematopoietic cells were 
recovered  and counted. The significance  of G-CSF in this 
system was tested by the addition of an antiserum to human 
G-CSF.  An eightfold increase in cell recovery was observed 
for hematopoietic cells grown in coculture with osteoblasts 
over a 2-wk period (Fig. 4). 55.4% of the osteoblast-induced 
increase in cell recovery was directly blocked by coincuba- 
tion of neutralizing anti-G-CSF antibody in the culture. It 
is interesting that 44.5%  of the growth activity produced 
by osteoblasts was not due to G-CSF, either alone or in com- 
bination with other osteoblast-derived cytokines. Further- 
more, in Wright-Geimsa cytospin preparations many of the 
hematopoietic cells recovered after 2 wk of coculture main- 
tained an immature morphology (23  _  6%  myeloblasts/ 
promyelocytes; 51.7  _+  5.5%  myelocytes/metamyelocytes; 
21  _+ 5% bands/polymorphonudear neutrophils; 4.3 _  0.6% 
monocytes). These data suggest that osteoblasts might pro- 
duce additional factors that support the survival and limited 
proliferation of primitive myeloid cells as well. 
The biologic data using CD34 + and the NFS-60 cell line 
in conjunction with the mRNA, and immunohistochemistry 
results  strongly  suggest  that  human  osteoblasts  produce 
G-CSE Osteoblast-derived G-CSF appears  to be accessible 
to target cells when it is associated with osteobhst's ceil mem- 
brane. The possible mechanisms by which growth factors be- 
come cell associated  or retained by components of the ex- 
tracellular matrix and presented to target cells have not yet 
been fully elucidated. Cell associated forms of M-CSF, c-kit 
ligand, IL-lol, and matrix-associated forms of IL-3 and GM- 
CSF have been described  (20,  21, 25-30). The implications 
of the experiments evaluating G-CSF production with bio- 
assays vs. ELISA of conditioned osteoblast medium suggest 
that either (a) immunoreactive G-CSF is diffusible only over 
extremely short distances  before inactivation; (b)  the neu- 
tralizing G-CSF antibody does not have access to the microen- 
vironment between osteoblasts and stem ceils; (c) directed 
cell-cell transfer of G-CSF occurs  between the osteoblasts 
and hematopoietic progenitors, as has been reported for IL-2 
(31); or (d) G-CSF or a closely related molecule is presented 
to hematopoietic cells as a cell membrane associated protein 
or bound in an active form to extracellular matrix molecules. 
Of interest,  at least three forms of G-CSF have been identified 
on immunoblots, including 18-, 28-, and 32-kD forms (32). 
To date it appears that the major secreted species is the 18-kD 
form, whereas the biological nature of the higher molecular 
mass  proteins  are  unknown  but  possibly  represent  cell- 
associated or inactive protein precursors  (32). We found no 
evidence for G-CSF detectable in either the LPS-treated or 
untreated osteoblast matrix fraction; until more extensive in- 
vestigation of osteoblast's extracellular matrix is performed 
however,  these data do not rule out such a possibility. 
It is interesting that the antibody to G-CSF neutralized 
only 55%  of the CD34 + cell's  proliferative  activity pro- 
duced by the osteoblasts  (Fig. 4). Thus, more than one factor 
produced by osteoblasts  may support the proliferation of he- 
matopoietic stem cells. At present we do not know the iden- 
tity of the molecule(s) which are responsible for this activity. 
In preliminary experiments neutralizing antibody to IL-6 and 
GM-CSF failed to affect proliferation of the NFS-60 cell line. 
It is possible  that unique osteoblast-derived cytokines are 
responsible  for proliferative effects on NFS-60  and CD34 + 
cells. These observations suggest that stem cell self-renewal 
is influenced by either osteoblast-derived cytokines or adhe- 
sive interactions between the two cell types or possibly both. 
In sum, strong evidence indicates that human osteoblasts 
produce cytokine signals that regulate hematopoiesis.  Hema- 
topoietic myeloid stem cell differentiation occurs in direct prox- 
imity to osteoblasts within the bone marrow cavity. We spec- 
ulate that this intimate physical association established early 
in life facilitates interactions between bone and hematopoi- 
etic cells. We determined that human osteoblasts are a con- 
stitutive source of the hematopoietic growth factor G-CSF. 
If osteoblasts are a major source of the colony stimulating 
cytokines in bone marrow, then understanding of the regu- 
lation of osteoblast-elaborated cytokines and the functional 
consequences of alterations in osteoblast metabolism are critical 
to our understanding of normal hematopoiesis. 
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